EGLN2 and cancer: Because docetaxel induces the JNK2/PHD1 signaling pathway and increases HIF-1α degradation (Figs 3 and 4), we investigated whether blocking the JNK2/PHD1 signaling pathway prevents docetaxel-mediated cancer cell death under hypoxic conditions through inhibition of HIF-1α degradation.